Related Experiment Video
Updated: Jul 4, 2026
13:45
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Leukotrienes, antileukotrienes and asthma
1Department of Pharmacology, Faculty of Medicine, Catholic University of the Sacred Heart, Largo F. Vito, 1, 00168 Rome, Italy. pmontuschi@rm.unicatt.it
Mini Reviews in Medicinal Chemistry
|June 10, 2008
Summary
Leukotrienes are inflammatory mediators involved in asthma. Blocking the cysteinyl-leukotriene 1 receptor with antagonists offers an effective asthma treatment strategy.
Area of Science:
- Biochemistry
- Pharmacology
- Immunology
Background:
- Leukotrienes (LTs), including LTB(4) and cysteinyl-LTs (CysLTs), are key inflammatory lipid mediators.
- CysLTs activate CysLT(1) and CysLT(2) receptors, playing a crucial role in asthma pathophysiology.
- Selective CysLT(1) receptor antagonists are established anti-asthmatic medications.
Purpose of the Study:
- To review leukotriene biosynthesis, metabolism, and mechanism of action.
- To examine the role of leukotrienes in asthma.
- To discuss therapeutic strategies involving leukotriene pathway inhibition and medicinal chemistry for CysLT(1) receptor antagonist design.
Main Methods:
- Review of scientific literature on leukotrienes and asthma.
- Analysis of drug development strategies for CysLT(1) receptor antagonists.
- Examination of structure-activity relationships for leukotriene pathway inhibitors.
Main Results:
- Leukotriene pathway inhibition is a validated therapeutic approach for asthma.
- Medicinal chemistry has successfully yielded potent and selective CysLT(1) receptor antagonists.
- Development strategies include structural analogs and compound library screening.
Conclusions:
- Targeting the leukotriene pathway, particularly CysLT(1) receptors, is effective for asthma management.
- Medicinal chemistry plays a vital role in designing targeted anti-asthmatic drugs.
- Understanding leukotriene function informs therapeutic interventions for inflammatory airway diseases.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...